Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00136578 · ClinicalTrials.gov registry record · Phase 1
Ispinesib In Combination With Carboplatin In Patients With Solid Tumors
A Phase 1 study of Solid Tumours, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT00136578: Completed Phase 1 study of Solid Tumours, sponsored by GlaxoSmithKline.
NCT00136578 is a Phase 1 study of Solid Tumours that has completed, run by GlaxoSmithKline. The registered enrollment target is 30 participants, below the 143-participant average among 9 other Solid Tumours trials with a reported enrollment target (79% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00136578, a Phase 1 study of Solid Tumours, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine the dose regimen of Ispinesib in combination with carboplatin in patients with solid tumors. Ispinesib is dosed by 1-hour intravenous infusion and carboplatin is dosed by 30 minute intravenous infusion every 3 weeks (on the same day). A patient may continue to receive treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times to measure the amount of both drugs in your body at specific times after the drug is given. Blood samples will also be taken for lab tests such as complete blood counts and clinical chemistries. Physical exams will be performed before each treatment with Ispinesib. During the treatment phase, the patients will undergo regular assessments for safety and clinical response.
Conditions Studied
Interventions
- DRUG carboplatin
- DRUG SB-715992
Study Locations (2)
Tennessee
- GSK Investigational Site - Nashville
Northumberland
- GSK Investigational Site - Newcastle upon Tyne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-10-20 |
| Est. Completion | 2006-10-25 |
| Phase | Phase 1 |
What the finished NCT00136578 record still lists
NCT00136578 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 143-participant average among 9 other Solid Tumours trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Solid Tumours appearing as the primary indexed condition, and to 2 interventions - of which carboplatin is the first listed.
NCT00136578 reports a single indexed study location in Tennessee, Northumberland.
Frequently Asked Questions
What is clinical trial NCT00136578 about?
NCT00136578 is a clinical study titled "Ispinesib In Combination With Carboplatin In Patients With Solid Tumors". The purpose of this study is to determine the dose regimen of Ispinesib in combination with carboplatin in patients with solid tumors. Ispinesib is dosed by 1-hour intravenous infusion and carboplatin is dosed by 30 minute intravenous infusion every 3 weeks (on the same day). A patient may continue ...
What is the current status of trial NCT00136578?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2004-10-20. Estimated completion is 2006-10-25.
What conditions does trial NCT00136578 study?
This clinical trial studies the following conditions: Solid Tumours.
What interventions are being tested in trial NCT00136578?
The interventions under investigation include: carboplatin (DRUG), SB-715992 (DRUG).
Who is sponsoring clinical trial NCT00136578?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00136578 being conducted?
This trial has 2 study locations across Tennessee, Northumberland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumours
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00136578's enrollment target sits among peer trials
30 10th of 9 the lowest of 9 other Solid Tumours trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumours trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it Helps
RECRUITING · Phase 1
-
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
RECRUITING · Phase 1
-
To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers
COMPLETED · Phase 1
-
To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers
COMPLETED · Phase 1
-
Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI